References

Gastrointestinal involvement in systemic sclerosis: an update

10.1097/bor.0000000000000645 · 2019 · External reference

Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management

10.1038/s41584-022-00900-6 · 2023 · External reference

Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence

10.1016/j.semarthrit.2010.03.002 · 2010 · External reference

Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease

10.1016/s2665-9913(22)00183-7 · 2022 · External reference

Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study

10.1038/s41598-020-57636-0 · 2020 · External reference

Adverse effects associated with long-term use of proton pump inhibitors

10.4068/cmj.2023.59.2.115 · 2023 · External reference

Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence

10.1002/prp2.651 · 2020 · External reference

Proton pump inhibitors associated with an increased risk of mortality in elderly: a systematic review and meta-analysis

10.1007/s00228-023-03606-0 · 2024 · External reference

The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association

10.1053/j.gastro.2017.01.031 · 2017 · External reference

High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis

10.1093/rheumatology/keaa332 · 2021 · External reference

Proton pump inhibitors in systemic sclerosis: should we exercise caution? Insights from a large-scale data analysis

10.1007/s10067-025-07686-4 · 2025 · External reference

A multi-national survey to identify clinicians’ perspectives concerning proton pump inhibitors in patients with systemic sclerosis

10.1016/j.semarthrit.2024.152419 · 2024 · External reference

A multinational survey investigating the unmet needs and patient perspectives concerning proton pump inhibitors in systemic sclerosis

10.1002/acr.25280 · 2024 · External reference

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

10.1136/ard-2024-226430 · 2025 · External reference

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

10.1136/annrheumdis-2013-204424 · 2013 · External reference

Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

10.1164/rccm.202202-0399st · 2022 · External reference

Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review

10.1136/rmdopen-2023-003426 · 2023 · External reference

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

10.1136/annrheumdis-2020-217455 · 2021 · External reference

Mapping and predicting mortality from systemic sclerosis

10.1136/annrheumdis-2017-211448 · 2017 · External reference

Computed tomography predictors of mortality or disease progression in systemic sclerosis-interstitial lung disease: a systematic review

10.3389/fmed.2021.807982 · 2021 · External reference

Predictors of progression in systemic sclerosis patients with interstitial lung disease

10.1183/13993003.02026-2019 · 2020 · External reference

Predicting trajectories of lung function decline in systemic sclerosis-related interstitial lung disease

10.1093/rheumatology/keaf270 · 2025 · External reference

Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease

10.1136/rmdopen-2024-004240 · 2024 · External reference

Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR National Italian Registry

10.1093/rheumatology/keaf457 · 2026 · External reference

Distinct clinical trajectories of gastrointestinal progression among patients with systemic sclerosis

10.1093/rheumatology/keae469 · 2025 · External reference

Associations between patterns of esophageal dysmotility and extra-intestinal features in patients with systemic sclerosis

10.1002/acr.25080 · 2023 · External reference

Abnormal esophageal scintigraphy associates with a distinct clinical phenotype in patients with systemic sclerosis

10.1002/acr2.11796 · 2025 · External reference

Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German network for systemic sclerosis

10.1093/rheumatology/kead023 · 2023 · External reference

The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes

10.1186/s13075-024-03355-0 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients

10.1111/nmo.13247 · 2018 · External reference

Delayed gastric emptying identifies a high-risk clinical subgroup in patients with systemic sclerosis

10.1093/rheumatology/keag070 · 2026 · External reference

Gastrointestinal dysmotility is associated with proton pump inhibitor refractory oesophagitis in patients with systemic sclerosis

10.1093/rheumatology/keae481 · 2025 · External reference

Prevalence and risk factors for medication-refractory reflux esophagitis in patients with systemic sclerosis in Japan

10.1007/s00535-024-02076-0 · 2024 · External reference

Systemic pharmacotherapy approaches for the treatment of systemic sclerosis

10.1080/14656566.2025.2470846 · 2025 · External reference

The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review

10.1093/rheumatology/keaf064 · 2025 · External reference